Study how liver impairment affects two investigational medicines
Part of Digestive system clinical trials.
This Phase 1 study tests how two investigational medicines move through the body and how safe they are in people with different levels of liver impairment, compared with healthy volunteers. It may help doctors understand dosing and safety for people with liver problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 70 years old when you are screened
- Your body mass index (BMI) must be between 18.5 and 40
- Your kidney function must be good enough (eGFR 60 or higher)
- You must be considered in good health by the study doctor, based on screening exams and lab tests
- If you have liver impairment: it must be mild, moderate, or severe and stable for at least 1 month
- If you have liver impairment: you must meet specific stability and complication limits (for example, no recent variceal bleeding or certain severe liver complications)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
This study tests how the body processes the drug inavolisib when taken by people with moderate or severe liver problems compared to those with healthy livers. It helps doctors understand the right dose for patients with liver impairment.
This research study tests how two experimental drugs (AZD9550 and AZD6234) work in people with different levels of liver function. The goal is to understand whether liver disease changes how the body processes these medications, which may help doctors safely treat patients with liver problems in the future.
This study tests how a new medicine, BI 3000202, is absorbed into the blood. It includes people with different levels of liver function (normal, mild, moderate, or severe) to see if liver problems affect how the medicine works.
This trial tests how a drug (BMS-986435) behaves in people with normal liver function versus those with liver problems. It also checks that the drug is safe for the heart.
This study tests a new medicine called RAY1225 in people with mild or moderate liver problems compared to those with healthy livers. It helps researchers understand how the liver affects the medicine, which could lead to safer dosing.
Hear when a new Hepatic Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.